The use of phenolic melanin precursors appeared more rational and promising for the development of melanogenesis-based anti-melanoma agents because the oxidation of phenolic compounds is only dependent on tyrosinase present in melanocytes and melanoma cells. The gene discussed is TYR; the disease is melanoma.